Nomads
BANGKOK / ACCESSWIRE / May 9, 2023 / HOYA Vision Care, a leader in optical technology innovation, continues to roll out the MiYOSMART sun range, with a planned reach of 30 countries, over the next few months following the soft launch in April 2023. The photochromic spectacle lenses, MiYOSMART Chameleon, and polarised spectacle lenses, MiYOSMART Sunbird, were developed to slow down myopia progression in children using D.I.M.S. Technology while providing protection from intense sunlight.[1-5] These two new products, along with the MiYOSMART clear spectacle lenses which launched in 2018, give children the freedom to comfortably take part in the activities they enjoy indoors and outdoors without compromising their eyesight.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Sun protection for children
MiYOSMART Chameleon and MiYOSMART Sunbird both provide protection from intense sunlight while simultaneously correcting the myopic refractive error and slowing myopia progression.[1-5] The new spectacle lenses utilise the same D.I.M.S. Technology used in the award-winning [6,7] and noninvasive MiYOSMART clear spectacle lenses, shown to slow myopia progression by 60% in children aged 8 to 13.[3] Due to its HOYA photochromic lens technology, MiYOSMART Chameleon is an all-in-one solution to myopia management and protected outdoor activity. It rapidly adapts to the level of sunlight and fades back to clear indoors in seconds.[8] Meanwhile, MiYOSMART Sunbird is the ideal addition to MiYOSMART clear spectacle lenses for extra protection from intense sunlight and glare.[1,9,10] It also offers vibrant colours and rich contrast in bright light, allowing children to fully experience the beauty of outdoors.[11]
"Children's vision is worth protecting. By acting today, we give them more opportunity tomorrow," said Frederiek Ysebaert, Managing Director of the Pediatric Care Business Unit at HOYA Vision Care. "With the launch of MiYOSMART sun spectacle lenses, inspired by our discussions with eye care professionals, we can enable children across the world to spend more time outdoors while protecting their eyes from intense sunlight, maximising the benefits of D.I.M.S. Technology on myopia progression."
Alongside the launch of the MiYOSMART sun range, HOYA Vision Care will launch "protect how they see the world," a dedicated global campaign to raise awareness of the importance of outdoor time and sun protection in children. Spending time outdoors may slow down myopia progression in children[6,7], and as such it is the most common recommended behavioural management for myopia given by eye care professionals.[8] However, as the majority of lifetime sun exposure occurs under the age of 21, it is necessary to prevent long-term eye damage to children's eyes with effective and reliable sun protection.[1,9] This is particularly important for myopic children using atropine eyedrops for myopia management, and those that are light-sensitive.[2,10,11]
From the launch in 2018 until the end of 2022, over four million MiYOSMART spectacle lenses were purchased by parents across the world.[18] With the launch of MiYOSMART Chameleon and MiYOSMART Sunbird, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.
Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.
About HOYA Vision Care
For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to eye care professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.
References
1. WSPOS. Sunlight Exposure & Children's Eyes Consensus Statement. 2016. Available at: https://www.wspos.org/wspos-sunlight-exposure-childrens-eyes-consensus-statement/ (Last accessed 28/03/2023)
2. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3-13.
3. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.
4. Lakkis C, Weidemann K. Evaluation of the performance of photochromic spectacle lenses in children and adolescents aged 10 to 15 years. Clin Exp Optom. 2006;89(4):246-252. .
5. Renzi-Hammond LM, Hammond BR Jr. The effects of photochromic lenses on visual performance. Clin Exp Optom. 2016;99(6):568-574.
6. Winners of the exhibition's grand prix. Inventions Geneva. N.D. Available from: https://inventions-geneva.ch/en/winners/ (Last accessed 28/03/2023)
7. Winners 2020. Silmo Paris. 2020. https://en.silmoparis.com/SILMO-d-OR/SILMO-dOrAwards/2020-Winners# (Last accessed 28/03/2023).
8. Hoya data on file. HOYA Internal Product Performance Validation. 09/2022
9. Hoya data on file. UVA and UVB transmittance for MiYOSMART photochromic and polarized sun spectacle lenses. 07/2022
10. Hoya data on file. Luminous transmittance for MiYOSMART polarized sun spectacle lenses. 07/2022
11. Quintana MS, Langa A, del Moral-Martinez I, et al. Polarized Filters Enhance Contrast Sensitivity When Glare Is Produced On A Flat Surface Under Photopic Conditions. Invest Ophthalmol Vis Sci. 2006;47(13):1225.
12. Ho CL, Wu WF, Liou YM. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int J Environ Res Public Health. 2019;16(14):2595.
13. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.
14. WSPOS. Myopia Survey Data. November 2022. Presented as part of WSPOS Symposium: Comprehensive Update on Myopia Management.19-20 November 2022. Available from: http://forum.wspos.org/symposium-part-1-comprehensive-update-on-myopia-management-2
15. Prevent Blindness. Children's Eyes are More Susceptible to Long-Term Damage from UV Rays. 2011. Available at: https://preventblindness.org/childrens-eyes-are-more-susceptible-to-longtermdamage-from-uv-rays/ (Last accessed 28/03/2023)
16. Li FF, Yam JC. Low-Concentration Atropine Eye Drops for Myopia Progression. Asia Pac J Ophthalmol (Phila). 2019;8(5):360-365.
17. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630.
18. Based on number of MiYOSMART lenses sold as per Hoya sales data on file as of December 2022.
Contact Information
Susan Brown
PR Lead
susan@wearenomads.com
8312334616
Related Images
SOURCE: HOYA Vision Care
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/753658/HOYA-Vision-Care-Launches-MiYOSMART-Sun-Spectacle-Lenses-Combining-Protection-From-Intense-Sunlight-With-Myopia-Management
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Reports Q1 2025 Record Results and Upward Revision to 2025 Outlook13.5.2025 08:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2025. First Quarter 2025 Net sales of $114.7 million, up 24.8% compared to the prior year's quarter. Net income of $15.3 million, up $13.1 million compared to the prior year's quarter. Diluted earnings per share of $0.16. Adjusted EBITDA of $43.1 million, up 30.6% compared to the prior year's quarter. Net income margin for the quarter improved to 13.4% compared to the prior year's quarter net income margin of 2.4%. Adjusted EBITDA Margin for the quarter improved to 37.6% compared to 36.0% for the prior year's quarter. Adjusted Earnings Per Share of $0.20. "We began 2025 with excellent momentum from strong demand across our end-markets," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "In the quarter, sales to our Original Equipment, Commercial Aftermarket and Defense marke
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud13.5.2025 07:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / May 13, 2025 / OMP, a global leader in supply chain planning solutions, announced today that its Unison PlanningTM platform has achieved SAP® certification as integrated with RISE with SAP S/4HANA® Cloud. Continuing its long history of providing SAP-certified integration, this milestone confirms Unison Planning's full support for S/4HANA environments and its compatibility with RISE with SAP. The integration delivers seamless, near-real-time connectivity between SAP and Unison Planning's advanced supply chain capabilities, reinforcing OMP's role as a trusted partner for navigating complex planning environments. "Achieving this certification highlights our commitment to innovation and enterprise-grade reliability," says Tom Wouters, Chief Product Officer at OMP. "It confirms our ability to support global businesses in their digital transformation journeys, especially those migrating to S/4HANA with RISE with SAP." OMP was recently recognized as a Leader
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory13.5.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is pleased to announce the integration of its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG (Gen-Plus) Contract Research and Development Organization (CRDO) in Munich, Germany. The move provides BioNxt with enhanced R&D capabilities, collaboration opportunities, and accelerated innovation potential within a major European biotech hub. The Company seeks to leverage the advanced and innovative infrastructure of the Gen-Plus Laboratory and harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt
Market Logic Software and Alchemy-RX Announce Strategic Partnership to Accelerate Transformation of Insights to Growth13.5.2025 02:00:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / May 13, 2025 / Market Logic Software, the market-leading SaaS provider of insight management solutions, announces a strategic partnership with Alchemy-Rx, a growth consultancy. Together, the two firms will help brands unlock the full value of insights - transforming research and data into topline growth. This partnership brings together complementary capabilities: Market Logic's AI-powered technology platform DeepSights™ - which centralizes and synthesizes research across knowledge sources - and Alchemy-Rx's proven methods to turning those insights into high-impact ideas. While Market Logic enables organizations to uncover trusted insights faster and more effectively, Alchemy-Rx helps brands act on those insights to fuel incremental revenue. "DeepSights is best-in-class-when it comes to insight management," said Richard Davies, Co-Founder of Alchemy-Rx. "This partnership combines our strengths. Making sense of multiple data sources to discover an insight
MicroVision Announces First Quarter 2025 Results12.5.2025 16:05:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / May 12, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its first quarter 2025 results. Key Business Highlights Established defense industry advisory board to accelerate strategic expansion and pursuit of revenue opportunities in the defense tech and military sectors. Elevated momentum toward near-term revenue opportunities from multiple leading industrial companies in the autonomous mobile robot (AMR) and automated guided vehicle (AGV) sector. Deepened executive leadership expertise, onboarding Glen DeVos, former CTO of Aptiv, as MicroVision's Chief Technology Officer, leading the Company's innovative product roadmapping and enhanced go-to-market strategy. Continued engagement with top-tier global automotive OEMs, with seven high-volume RFQs for passenger vehicles and custom development opportunities. Ramped production to meet anticipated volume demand, ensur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom